Epidemiology and Care in Acne inversa

Epidemiology and Care in Acne inversa - EpiCAi

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025315

Enrollment

2000

Registered

2021-06-17

Start date

2021-12-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L73.2

Interventions

Group 1: All patients who have agreed to the documentation of their treatment with LAight® therapy in the LENICURA software will be invited to participate in the study. This is done on the one hand by

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Acne inversa (hidradenitis suppurativa) of all severities (Hurley I-III) 2. Patient is treated with LAight® and documented via the software 3. Smartphone or tablet with access to the patient portal of the software

Exclusion criteria

Exclusion criteria: Insufficient knowledge of the German language

Design outcomes

Primary

Measure	Time frame
The study is expected to provide new insights into patient pathways through the healthcare system, disease progression, recurrence frequency, trigger factors, risk factors, quality of life, effectiveness of therapies, and other.	—

Countries

Germany

Contacts

Public ContactKatharina Reinhard

LENICURA GmbH

info@lenicura.de+49611 95008500

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026